Literature DB >> 20406627

Involvement of dopamine receptors in the antidepressant-like effect of melatonin in the tail suspension test.

Ricardo W Binfaré1, Michela Mantovani, Josiane Budni, Adair Roberto S Santos, Ana Lúcia S Rodrigues.   

Abstract

Melatonin was previously shown to produce an antidepressant-like effect in the tail suspension test. In this work the mechanisms underlying its antidepressant-like effect were further studied by investigating the involvement of the dopaminergic system in its antidepressant-like effect in the tail suspension test. The effect of melatonin (1mg/kg, i.p.) was prevented by the pretreatment of mice with haloperidol (0.2mg/kg, i.p., a nonselective dopaminergic receptor antagonist), SCH23390 (0.05 mg/kg, s.c., a selective dopamine D1 receptor antagonist), and sulpiride (50mg/kg, i.p., a selective dopamine D2 receptor antagonist). The i.p. administration of melatonin (0.01 mg/kg) or fluoxetine (1mg/kg, a serotonin reuptake inhibitor) in combination with SFK38393 (0.1mg/kg, s.c., a dopamine D1 receptor agonist) reduced the immobility time in the tail suspension test as compared with either drug alone. Moreover, the pretreatment with melatonin (0.01 mg/kg, i.p.) produced a synergistic effect with apomorphine (0.5 microg/kg, i.p., a dopamine D2 receptor agonist), but the pretreatment with fluoxetine (1mg/kg, i.p.) was ineffective to potentiate the effect of apomorphine. Dopamine receptor antagonists or agonists alone or in combination with melatonin did not affect locomotor activity. These results indicate that the antidepressant-like effect of melatonin in the tail suspension test is likely mediated by an interaction with the dopaminergic system, through an activation of dopamine D1 and D2 receptors. Our data confirm the previous notion on the role exerted by melatonin in depression, suggesting that it might be further investigated as an alternative for the management of depression associated with anhedonia. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406627     DOI: 10.1016/j.ejphar.2010.04.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Optogenetic investigation of neural circuits underlying brain disease in animal models.

Authors:  Kay M Tye; Karl Deisseroth
Journal:  Nat Rev Neurosci       Date:  2012-03-20       Impact factor: 34.870

Review 2.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

3.  Quinpirole Increases Melatonin-Augmented Pentobarbital Sleep via Cortical ERK, p38 MAPK, and PKC in Mice.

Authors:  Sa-Ik Hong; Seung-Hwan Kwon; Ji-Young Hwang; Shi-Xun Ma; Jee-Yeon Seo; Yong-Hyun Ko; Hyoung-Chun Kim; Seok-Yong Lee; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2016-03-01       Impact factor: 4.634

4.  Repetitive Neonatal Erythropoietin and Melatonin Combinatorial Treatment Provides Sustained Repair of Functional Deficits in a Rat Model of Cerebral Palsy.

Authors:  Lauren L Jantzie; Akosua Y Oppong; Fatu S Conteh; Tracylyn R Yellowhair; Joshua Kim; Gabrielle Fink; Adam R Wolin; Frances J Northington; Shenandoah Robinson
Journal:  Front Neurol       Date:  2018-04-13       Impact factor: 4.003

5.  Programmed environmental illumination during autologous stem cell transplantation hospitalization for the treatment of multiple myeloma reduces severity of depression: A preliminary randomized controlled trial.

Authors:  Heiðdís B Valdimarsdottir; Mariana G Figueiro; William Holden; Susan Lutgendorf; Lisa M Wu; Sonia Ancoli-Israel; Jason Chen; Ariella Hoffman-Peterson; Julia Granski; Nina Prescott; Alejandro Vega; Natalie Stern; Gary Winkel; William H Redd
Journal:  Cancer Med       Date:  2018-08-11       Impact factor: 4.452

6.  Antidepressant-Like Effect of Terpineol in an Inflammatory Model of Depression: Involvement of the Cannabinoid System and D2 Dopamine Receptor.

Authors:  Graziela Vieira; Juliana Cavalli; Elaine C D Gonçalves; Saulo F P Braga; Rafaela S Ferreira; Adair R S Santos; Maíra Cola; Nádia R B Raposo; Raffaele Capasso; Rafael C Dutra
Journal:  Biomolecules       Date:  2020-05-20

Review 7.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.